(Q33424311)

English

Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Juan Sainz

6

0 references

author name string

Paloma García-Martín

1

1 reference

Europe PubMed Central

26 July 2017

Carolina Alarcón-Payer

2

1 reference

Europe PubMed Central

26 July 2017

Elisa López-Fernández

3

1 reference

Europe PubMed Central

26 July 2017

Lucía Moratalla

4

1 reference

Europe PubMed Central

26 July 2017

Antonio Romero

5

1 reference

Europe PubMed Central

26 July 2017

Rafael Ríos

7

1 reference

Europe PubMed Central

26 July 2017

Manuel Jurado

8

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

9 July 2015

1 reference

Europe PubMed Central

26 July 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

26 July 2017

49

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

986-994

1 reference

Europe PubMed Central

26 July 2017

Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Rapamycin for refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents.

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Prediction of veno-occlusive disease using biomarkers of endothelial injury

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Clinical pharmacokinetics of sirolimus

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Clinical relevance of pharmacogenetics

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Thrombotic microangiopathy in haematopoietic cell transplantation: an update

1 reference

https://api.crossref.org/works/10.1177%2F1060028015593369

21 January 2018

Identifiers

10.1177/1060028015593369

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33424311&oldid=1956324619"